Tulobuterol is a potential therapeutic drug in congenital myasthenic syndrome

Pediatr Int. 2022 Jan;64(1):e15115. doi: 10.1111/ped.15115.

Authors

Kaori Miyana¹, Akihiko Ishiyama², Yoshihiko Saito³, Ichizo Nishino³

Affiliations

¹ Department of Pediatrics, Japanese Red Cross Medical Center, Tokyo, Japan.
² Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
³ Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

PMID: 35396808
DOI: 10.1111/ped.15115

No abstract available

Keywords: DOK7; congenital myasthenic syndrome; therapeutic agent; tulobuterol; β2-adrenergic agonist.

MeSH terms

Adrenergic beta-2 Receptor Agonists / therapeutic use
Humans
Myasthenic Syndromes, Congenital* / drug therapy
Myasthenic Syndromes, Congenital* / genetics
Terbutaline / analogs & derivatives
Terbutaline / therapeutic use

Substances

Adrenergic beta-2 Receptor Agonists
tulobuterol
Terbutaline